Sign In
Buy MYGN
$2.86
-2.51 (-46.74%)
At Close: Jul 31, 2026
ANGLE partners with Myriad Genetics on enhanced patient treatment approach in cancer
02:41am, Wednesday, 20'th Aug 2025
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) has struck a collaboration with Myriad Genetics of the US to explore whether cancer DNA captured from blood can be used alongside existing tumour tissue tests. The li
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
08:30am, Monday, 18'th Aug 2025
SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been pro
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
08:00am, Wednesday, 13'th Aug 2025
Cancer Risk Survey shows that more than half of women at high-risk for hereditary cancer would feel "empowered" by more advanced screening like genetic testing Cancer Risk Survey shows that more than
Myriad: HCT In Oncology Continues To Deliver Increased Volume And Revenue Growth
05:51pm, Wednesday, 06'th Aug 2025
Myriad Genetics posted Q2 2025 revenue growth of 1% year-over-year, but adjusted for one-time events, growth would have been 5%. Key growth drivers include expanding Hereditary Cancer Testing to unaff
Myriad Genetics, Inc. (MYGN) Q2 2025 Earnings Call Transcript
04:14am, Wednesday, 06'th Aug 2025
Myriad Genetics, Inc. (NASDAQ:MYGN ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Mark S. Verratti - Chief Operating Officer Matthew Scalo - Senior Vice President of
Myriad Genetics (MYGN) Q2 Revenue Up 6%
08:51pm, Tuesday, 05'th Aug 2025
Myriad Genetics (MYGN) Q2 Revenue Up 6%
Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics
07:31pm, Tuesday, 05'th Aug 2025
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Myriad Genetics (MYGN) Q2 Earnings and Revenues Surpass Estimates
06:56pm, Tuesday, 05'th Aug 2025
Myriad Genetics (MYGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to earnings of $0.05 per share a year ago.
Myriad Genetics Reports Second Quarter 2025 Financial Results; Raises 2025 Revenue Guidance Following Positive Business Momentum
04:05pm, Tuesday, 05'th Aug 2025
Myriad Genetics announced financial results for its second quarter ended June 30, 2025, updated full-year 2025 financial guidance on business performance.
INVESTOR ALERT: Investigation of Myriad Genetics, Inc. (MYGN) Announced by Holzer & Holzer, LLC
01:04pm, Wednesday, 25'th Jun 2025
ATLANTA, June 25, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) complied with federal securit
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
09:26am, Monday, 16'th Jun 2025
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Myriad (MYGN) Up 23.9% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 05'th Jun 2025
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
09:00am, Tuesday, 03'rd Jun 2025
Screening test provides prenatal risk assessment for common genetic conditions in one blood draw without the need for paternal testing
Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
04:05pm, Tuesday, 27'th May 2025
Two Molecular Residual Disease (MRD) studies highlighting clinical data among seven new studies to be shared by Myriad and collaborators Two Molecular Residual Disease (MRD) studies highlighting clini
Levi & Korsinsky Investigates Myriad Genetics, Inc. (MYGN) Over Possible Securities Fraud
10:15am, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Myriad Genetics, Inc. ("Myriad Genetics, Inc.") (NASDAQ:MYGN) concerning p
